Diagnosis:\nBasal cell carcinoma (stage IIA, pT3a, M0, N2a) - diagnosed September 2022\n- matching mutations in 3 distinct samples\nCurrent treatments\n14/08/24 completed targeted RT to 3 sites: Right forearm + right shoulder blade, dose 20gy/5# - as of 28/11/24 - partial response\nBetnovate face and arms\nClobetasol cream torso\nCo-morbidities:\nAnxiety\nLow Vitamin D\nOther medications:\nCalcium, Vitamin D3.\nNo known drug allergies.\nPrevious treatments prior to diagnosis of BCC:\nHydrocortisone\nCryotherapy (PUVA); approx 5 months, minimal response, scarring\nAzathioprine (several weeks); stopped due to liver enzymes\nMycophenolate topical (? 4 - 7 months); partial response\nDupilumab (Dupixent); 5 - 6 months (2021 - April 2022); minimal response\nUstekinumab 90mg started May/June 2022; no response\nPrevious Investigations\nCT 12/07/24: Unilateral cervical and epitrochlear nodes, larger and more prominent than baseline, that are again felt most likely to be reactive in nature. Dermal nodules and regions of indurated tissue with mild enhancement, consistent with known BCC. No evidence of distant metastatic disease.\nToday's review:\n- Seen with Dr Martinez.\n- Sarah has not observed any meaningful change in her lesions over the past fortnight.\n- She continues to experience localized burning, though this is not impacting her work.\n- Her energy remains steady, though reports occasional dizziness.\n- The previously treated sites on the forearm and shoulder blade with radiotherapy have now partially responded.\n- No A symptoms\n- Has strong support at work (lives with Partner)\n- Overall - lesions appear stable from previous.\n- No palpable masses\nPlan:\nContinue with Vismodegib\nReview in 3 weeks in order to evaluate response (images taken today and stored to Records)\nClobetasol in petroleum jelly prescribed twice daily\nBetamethasone lotion twice daily to involved areas\nReview in 3 weeks.\nRoutine labs today (ordered)\nKind\nregards,\nDr Peterson\nOncology SpR